Newsfeeds - Spark Newswire

2 minute read

Galectin Therapeutics Provides Final Randomization Status Of NAVIGATE, Its Seamless, Adaptive Phase 2b/3 Study of Belapectin In Patients With Liver Cirrhosis Caused By Non-Alcoholic Steatohepatitis

Today, 9:54 AM

Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, announced that in late December 2022, it ended the enrollment of new patients into NAVIGATE, its

GALT

2 minute read

Movers

12 Health Care Stocks Moving In Tuesday’s Intraday Session

By Benzinga Insights

Today, 9:54 AM

Gainers Lixte Biotech Hldgs (NASDAQ:LIXT) shares rose 97.3% to $1.6 during Tuesday’s regular session. Trading volume for this…

CDIO

1 minute read

Galectin Therapeutics Q3 EPS $(0.14), Same YoY

By Benzinga Newsdesk

Today, 9:54 AM

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.14) per share. This is unchanged from the same period last year.

GALT

7 minute read

This Healthcare Stock Tumbled 43%; Here Are 88 Biggest Movers From Yesterday

By Lisa Levin

Today, 9:54 AM

Gainers Athersys, Inc. (NASDAQ: ATHX) climbed 71.1% to close at $0.3250 on Thursday after gaining 10% on Wednesday. Athersys is expected to release its Q2 financial results on Thursday, August 11, 2022.

AMPS

2 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s After-Market Session

By Benzinga Insights

Today, 9:54 AM

Gainers

ALVR

4 minute read

62 Biggest Movers From Yesterday

By Lisa Levin

Today, 9:54 AM

Gainers Missfresh Limited (NASDAQ: MF) jumped 51.1% to close at $0.2450 on Wednesday.

AFRM

1 minute read

HC Wainwright & Co. Maintains Buy on Galectin Therapeutics, Lowers Price Target to $11

By Benzinga Newsdesk

Today, 9:54 AM

HC Wainwright & Co. analyst Ed Arce maintains Galectin Therapeutics (NASDAQ:GALT) with a Buy and lowers the price target from $14 to $11.

GALT

1 minute read

Recap: Galectin Therapeutics Q1 Earnings

By Benzinga Insights

Today, 9:54 AM

Galectin Therapeutics (NASDAQ:GALT) reported its Q1 earnings results on Monday, May 16, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

GALT

1 minute read

Galectin Therapeutics Q1 EPS $(0.17) Down From $(0.11) YoY

By Benzinga Newsdesk

Today, 9:54 AM

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.17) per share. This is a 54.55 percent decrease over losses of $(0.11) per share from the same period last year.

GALT

44 minute read

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

Today, 9:54 AM

On Wednesday, 807 companies reached new 52-week lows.

AADI